Search results
Showing 31 to 45 of 52 results for doxorubicin
November 2002 TA389 Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine...
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)
This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.